News & Press Releases Swedish

Scandinavian ChemoTech har klarat slutrevisionen av IQwave och ökar sina chanser till CE märkning innan deadline

ChemoTech kan nu summera stora framsteg efter att ha klarat den tre dagar långa och intensiva revision av Bolagets kvalitetssystem samt granskning av dess kritiska processer som krävs för CE-märkning av medicinteknisk utrustning inom EU.

Read more

Analys om Scandinavian ChemoTech AB publicerad av Erik Penser Bank

Erik Penser Bank initierar en analysbevakning av Scandinavian ChemoTech, med bedömningen att aktien har en hög risk, men med en stor potentiell uppsida.

Read more

Scandinavian ChemoTech kommer att inleda en förstudie för att undersöka möjligheten att starta ett kliniskt program med inriktning på pankreascancer

ChemoTechs styrelse har idag beslutat att påbörja en förstudie tillsammans med en grupp ledande specialister inom pankreascancer (cancer i bukspottkörteln) i USA och Europa i syfte att skapa ett internationellt kliniskt samarbete.

Read more

News & Press Releases English

Scandinavian ChemoTech has passed the final revision of IQwave and increases its chances of CE marking before the deadline

ChemoTech can now sum up great progress after completing the three-day long and intensive revision of the Company's quality system and review of its critical processes required for CE marking of medical devices in the EU.

Read more

Analysis of Scandinavian ChemoTech AB published by Erik Penser Bank now available in English

In accordance with the newsletter that was published the 5[th] of January 2021, Erik Penser Bank has now begun the implementation of a number of commissioned analyses, the first of which has been published and is available on ChemoTech's website in English: https://www.chemotech.se/investor-relations/financial-analysis/ (https://www.chemotech.se/wp-content/uploads/2021/05/Research-Coverage-Erik-Penser-Bank-ENG.pdf)

Read more

Scandinavian ChemoTech will launch a feasibility study to investigate the possibility of starting a clinical program focusing on pancreatic cancer

ChemoTech's Board of Directors has today decided to begin a feasibility study along with a group of leading specialists in pancreatic cancer in the US and Europe in order to create an international clinical collaboration.

Read more

Chemotech Videos

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish)

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both TSE- Tumour Specific Electroporation and the first generation electrochemotherapy for the treatment of a range of different types of tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.